Biomednewsbreaks - Annovis Bio Inc. Advances Alzheimer's Phase 3 Trials With Strong FDA Support And Financial Backing

(MENAFN- Investor Brand Network) Annovis Bio (NYSE: ANVS)
provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer's disease (“AD”) and Parkinson's disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened its intellectual property with new patents for buntanetap combination therapies and expanded its team with the appointment of Senior Clinical Scientist Dr. Matthew Peterson to support trial quality and completion.

To view the full press release, visit

About Annovis Bio Inc.

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

For more information, visit the company's website at
,
and social channels
LinkedIn ,
X
and
YouTube .

NOTE TO INVESTORS:
The latest news and updates relating to ANVS are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN11112024000224011066ID1108873257